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Renovascular hypertension (RVH) is the most
common cause of surgically correctable hyperten-
sion. RVH develops through activation of the renin-
angiotensin system; however, coincident sympathetic
stimulation may play a role in augmenting hyperten-
sion.1 The plasma concentrations of norepinephrine
BASIC RESEARCH STUDIES
Role of neuropeptide Y in the
development of two-kidney, one-clip
renovascular hypertension in the rat
Lynn H. Shin, MD, Peter S. Dovgan, MD, Timothy J. Nypaver, MD, Oscar
A. Carretero, MD, and William H. Beierwaltes, PhD, Detroit, Mich 
Objective: Along with the renin-angiotensin system, sympathetic stimulation may con-
tribute to renovascular hypertension. The vasoactive peptide neuropeptide Y (NPY) is co-
released with and potentiates the pressor effects of norepinephrine through the Y-1 recep-
tor. NPY, by exaggerating sympathetic activity, may contribute to renovascular hyperten-
sion, possibly by augmenting adrenergic-mediated renin release. This was studied by
determining the effect of continuous Y-1 blockade on the development of two-kidney,
one-clip renovascular hypertension and the effect of NPY on in vitro renin release.
Methods: Mean arterial pressure and renal blood flow responses to NPY (10 µg/kg,
administered intravenously) were measured in five anesthetized Sprague-Dawley rats
before and after BIBO3304TF administration to test the Y-1 antagonist BIBO3304TF.
In hypertension studies, 28 rats underwent left renal artery clipping. Of these, 13 were
implanted with a mini-osmotic pump for continuous BIBO3304TF infusion (0.3 µg/h,
administered intravenously); the other 15 underwent sham implantation. Systolic blood
pressure was then monitored for 4 weeks. Finally, in vitro renin release was measured
from renal cortical slices (n = 6-12) incubated with NPY (10–8 to 10–6 mol/L) or NPY
plus the adrenergic agonist isoproterenol (10–4 mol/L).
Results: BIBO3304TF attenuated the NPY-induced increase in mean arterial pressure by
54% (P < .02) and the NPY-induced decrease in renal blood flow by 38% (P < .05). In 4-
week hypertension studies, systolic blood pressure in clipped controls increased from 130
± 3 mm Hg to 167 ± 6 mm Hg (P < .01), whereas BIBO3304TF-treated rats had no sig-
nificant increase (125 ± 3 mm Hg to 141 ± 8 mm Hg). Final systolic blood pressure was
26 mm Hg lower in BIBO3304TF-treated rats than in controls (P < .01). In renal corti-
cal slices, no NPY effect was observed in basal or isoproterenol-stimulated renin release.
Conclusions: The Y-1 receptor antagonist BIBO3304TF attenuated acute pressor
responses to NPY and blunted the development of two-kidney, one-clip renovascular
hypertension in rats. NPY may contribute to the hypertensive response in this renovas-
cular hypertension model. Our in vitro data do not suggest that this is due to NPY
enhancement of renin release. (J Vasc Surg 2000;32:1015-21.)
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have been shown to be elevated in early-phase RVH.2
Furthermore, renal nerve stimulation, as well as
direct adrenergic receptor activation with norepi-
nephrine, epinephrine, or isoproterenol (iso),
increases renin release in both in vitro and in vivo
studies.3-5 This augmentation of renin release is
probably mediated by adrenergic agonists at the level
of the juxtaglomerular cells. Thus the sympathetic
system, through adrenergic-mediated augmentation
of renin release, may contribute to or exacerbate the
hypertensive response to renal artery stenosis.
Neuropeptide Y (NPY) is a 36-amino acid
vasoactive peptide that is co-released with norepi-
nephrine in the sympathetic nerves innervating
smooth muscle. NPY greatly potentiates the pressor
effects of norepinephrine in the peripheral smooth
muscle through activation of the Y-1 receptor.6,7
Although the sympathetic nervous system is ubiqui-
tous, and thus so is NPY, the effect of NPY on the
peripheral vasculature appears to be selectively medi-
ated through this NPY-Y1 receptor. Other physio-
logic functions of the sympathetic system are medi-
ated through different NPY receptors. Renal artery
stenosis may be associated with increased NPY activ-
ity, with subsequent enhancement of sympathetic
effects. This NPY contribution to the hypertensive
state may occur either directly or through adrenergic
stimulation of renin secretion.
We hypothesized that NPY, by exaggerating sym-
pathetic activity, contributes to the hypertensive
response in RVH and that this response could be medi-
ated through augmentation of adrenergic-mediated
renin release. To test this hypothesis, chronic selective
Y-1 receptor blockade was performed in a rat model of
two-kidney, one-clip (2K1C) RVH to determine the
NPY influence on hypertension development.
Additional experiments were conducted in kidney slices
to investigate the in vitro effects of NPY on basal and
adrenergic-stimulated renin release.
MATERIALS AND METHODS
Acute hemodynamic studies. Initial studies
were performed to determine the effectiveness of the
selective Y-1 antagonist BIBO3304TF (Boehringer
Ingelheim Pharma, Biberach, Germany). Five
Sprague-Dawley rats (Charles River, Portage, Mich),
each weighing 250 to 300 g, fasted overnight and
were then anesthetized with Inactin (1.25 mg/kg,
administered intraperitoneally [ip]; Research
Biochemical International, Natick, Mass). The right
femoral artery and vein were cannulated. The left
renal artery was exposed by means of a midline inci-
sion, and an electromagnetic flow probe (Carolina
Medical Electronics, King, NC) was positioned to
measure renal blood flow (RBF).
The dose of the Y-1 antagonist BIBO3304TF cho-
sen was equivalent to doses used in subsequent exper-
iments and based on the maximal delivery of the drug
via a mini-osmotic pump (0.3 µg/h). The anes-
thetized rat was given a pharmacologic pressor dose of
NPY (10 µg/kg, administered intravenously [iv];
Bachem, King of Prussia, Pa). After a 30-minute
recovery period, the rat received an intravenous bolus
of BIBO3304TF (0.3 µg) followed by a constant
intravenous infusion (0.3 µg/h). After 30 minutes, the
rat received a second bolus of NPY (10 µg/kg iv).
Mean arterial blood pressure (MAP) and RBF were
recorded throughout the study. The volume of each
bolus was 200 µL, and all infusions were delivered at
51 µL/min. Control studies were performed through
use of vehicle (deionized distilled water) instead of the
Y-1 antagonist BIBO3304TF.
Hypertension studies. The effect of chronic Y-1
receptor inhibition was studied in animals undergoing
renal artery clipping. Twenty-eight male Sprague-
Dawley rats, each weighing 175 to 200 g, fasted
overnight and then were anesthetized with sodium
pentobarbital (50 mg/kg ip; Abbott, North Chicago,
Ill). The left renal artery was exposed through use of
a flank approach, and a silver clip with an internal
diameter of 0.23 mm was placed across the artery,
avoiding excessive dissection of the adventitia. The
wound was closed in two layers with 4-0 silk.
Thirteen of the 28 rats then underwent placement
of a mini-osmotic pump (Alza, Palo Alto, Calif),
which allowed for 4-week continuous delivery of the
Y-1 antagonist BIBO3304TF. In accord with the
manufacturer’s instructions, each pump was fitted
with a catheter (PE-60 fused to PE-10). The pump
was then filled with 230 µL of BIBO3304TF dis-
solved in deionized double-distilled water (1.0
mg/mL) and primed for at least 40 hours in sterile
0.9% saline solution at 37°C. Through a small mid-
ventral incision, the pump was inserted into the peri-
toneal cavity of the anesthetized animal. The catheter
was tunneled beneath the inguinal ligament into the
groin, then secured in the femoral vein. The calculat-
ed drug delivery rate was 0.3 µg/h. The remaining 15
of the 28 clipped rats underwent sham surgery with-
out pump placement; the operation consisted of a
midventral incision and ligation of the femoral vein.
(Pumps have been used in previously published stud-
ies in 2K, 1C rats without any effect on the develop-
ment of hypertension.) All of the incisions were
closed with 4-0 silk and painted with collodion. The
animals were allowed to recover on warming blankets.
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The rats were fed standard rat chow and tap
water ad libitum. Systolic blood pressures (SBPs)
were measured by means of tail cuff plethysmogra-
phy (IITC Inc Life Science Instruments, Woodland
Hills, Calif) daily for 3 days, then weekly for 4
weeks. The rats had been trained for several days
before the experiment to minimize the stress of tail
cuff measurements. Paired analysis was run of the
change in SBP in each animal from clipping to the
end of 4 weeks. At the end of 4 weeks, the rat was
anesthetized with Inactin (1.25 mg/kg, ip) and
explored by means of a midventral incision. The
appearance of the kidneys and the pump position
were noted. The animal was then killed by transect-
ing the aorta. The heart and kidneys were removed
and weighed. Residual drug in the pump reservoirs
was measured by volume.
Renin studies. In vitro studies were performed
to determine the influence of NPY on renin release
from renal cortical slices. Adult male Sprague-
Dawley rats, each weighing 250 to 300 g, fasted
overnight and were then anesthetized (Inactin, 1.25
mg/kg ip). The kidneys were exposed through a
midline incision, and the infrarenal aorta was isolat-
ed and cannulated. The proximal aorta was then
cross-clamped below the diaphragm, and the kid-
neys were perfused with 30 mL of physiologic medi-
um. The medium used for perfusion and incubation
was the bicarbonate buffer medium of Churchill and
Churchill containing the following (in millimoles):
NaCl, 125; NaHCO3, 19; KCl, 4; CaCL2, 2.6;
NaH2PO4, 1.2; MgSO4, 0.8; and glucose, 0.2
gm/100 mL.8 The medium was equilibrated with a
mixture of 95% O2 and 5% CO2 to a pH of 7.4 at a
temperature of 37°C.
After perfusion, the kidneys were harvested and
placed in cold medium. Two 500-µm slices were
obtained from each lateral surface of the decapsulat-
ed kidneys with a Stadie-Riggs microtome. Slices
from each half were paired for control and experi-
mental incubations. Cortical slices were equilibrated
at 37°C for 30 minutes in 25-mL Erlenmeyer flasks,
each containing 10 mL of medium and 0.1 g/100
mL of heat-inactivated bovine serum albumin
(Difco, Detroit, Mich). The flasks were agitated at
one revolution per second and gassed with 95% O2
and 5% CO2.
To study the effects of NPY on basal renin
release, we added NPY in 500 µL of medium to the
slices for final concentrations of 10–6 mol/L to 10–8
mol/L (for NPY 10–8 mol/L, n = 6; for NPY 10–7
mol/L, n = 8; for NPY 10–6 mol/L, n = 8). Control
slices received medium only. A 200-µL aliquot of
incubation medium was taken for renin assay before
and 30 minutes after the addition of NPY. To study
adrenergic-stimulated renin release, we equilibrated
slices as described; iso (10–5 mol/L; Sigma, St
Louis, Mo) was then added to the medium for the
second 30-minute incubation (n = 12). The proto-
col was also performed with NPY (10–6 mol/L)
added to slices 5 minutes before the addition of iso.
Renin concentration in the incubation medium
was determined by radioimmunoassay for the genera-
tion of angiotensin I (AngI) in the presence of exoge-
nous rat angiotensinogen after the method of Haber
et al,9 as previously described.10 Slices were oven
dried and weighed. Renin concentration was correct-
ed by the dry tissue weight and incubate volume and
is expressed in nanograms of AngI per hour per mil-
ligram of tissue per 30 minutes of incubation. Renin
release was determined as the difference in concentra-
tion between collections obtained before and 30 min-
utes after the addition of drug(s).
All animal protocols were approved by the
Institutional Animal Care and Use Committee in
compliance with the Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal
Resources, Commission on Life Science, National
Research Council. Washington DC: National
Academy Press; 1996).
Statistical analysis. Data were analyzed through
use of paired or unpaired Student t tests (SigmaPlot;
SPSS Inc, Chicago, Ill). Numbers presented repre-
sent means ± SEs. A P value of less than .05 was con-
sidered to represent statistical significance.
RESULTS
Acute hemodynamic studies. The bolus infu-
sion of NPY (10 µg/kg iv) increased the MAP by 13
± 2 mm Hg and decreased RBF by 25.8% ± 3.6% (Fig
1). After Y-1 receptor inhibition with BIBO3304TF,
NPY increased the MAP by only 6 ± 2 mm Hg—a
54% reduction in the pressor response (P < .02).
BIBO3304TF also attenuated the NPY-induced
decrease in RBF to 16.0% ± 3.1% (P < .05; Fig 1). In
control animals, NPY raised the MAP by 15 ± 2 mm
Hg and lowered RBF by 25.5% ± 1.9%. After admin-
istration of vehicle, NPY effects were not significant-
ly attenuated (the MAP increase was 14 ± 3 mm Hg;
the RBF decrease was 32.1% ± 9.2%). Although the
initial bolus of BIBO3304TF transiently decreased
the MAP and increased RBF, these parameters
returned to baseline after a few minutes. Thus the
infusion of BIBO3304TF did not cause any sustained
alterations in either basal MAP or RBF.
Hypertension studies. In control rats, renal
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artery clipping increased SBP from 130 ± 3 mm Hg
to 167 ± 6 mm Hg over the 4-week observation
period (P < .01). However, clipped rats that received
the chronic infusion of Y-1 inhibitor had a non-
significant rise in SBP, from 125 ± 3 mm Hg to 141
± 8 mm Hg (Fig 2). This final SBP of the treated rats
was 26 mm Hg lower (167 ± 6 mm Hg vs 141 ± 8
mm Hg) than that of the clipped controls (P < .01).
When the animals were killed, all pumps and
catheters appeared intact, and the residual volume of
drug solution was less than 0.02 mL in all reservoirs.
There was no difference in mean body weights
between the control animals and the treated animals
(358 ± 10 g and 351 ± 13 g, respectively), nor was
there a difference in mean heart weight (1.42 ± 0.07
g vs 1.31 ± 0.16 g) or mean left (clipped) kidney
weight (1.09 ± 0.11 g vs 1.29 ± 0.10 g). Mean right
(unclipped) kidney weight was less in the treated
group than in the control group (1.48 ± 0.06 g vs
1.68 ± 0.07 g, respectively; P < .05). The left:right
kidney weight ratio was greater in the treated group
than in the control group (0.87 ± 0.04 vs 0.67 ±
0.07, respectively; P < .03).
Kidney cortical slices. The Table illustrates that
with incubation of the kidney cortical slices, renin
release did not significantly change at the varying
NPY concentrations (10–6 mol/L to 10–8 mol/L).
Incubation of kidney slices with 10–4 mol/L iso
resulted in the expected stimulation of renin release
from 33.6 ± 7.4 ngAng/h/mg/30 min unstimulated
to 70.4 ± 10.8 ngAng/h/mg/30 min stimulated
with iso (P < .01; Fig 3). After preadministration of
NPY 10–6 mol/L, the increase induced by iso was no
longer significant, changing from 21.2 ± 7.7
ngAng/h/mg/30 min unstimulated to 37.9 ± 5.5
ngAng/h/mg/30 min stimulated with iso. Although
there was a trend toward an inhibitory effect of NPY
on iso-stimulated renin release from the renal cortical
slices, this did not achieve significance (P = .09; Fig 3).
DISCUSSION
The role of the renin-angiotensin system in the
development of RVH has been studied and used in
clinical practice for many years. The renin-
angiotensin system is known to play a key role in the
elevation of blood pressure, but there is evidence that
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Fig 1. A, Effect of NPY on MAP in anesthetized rats, before and after administration of Y-1 antagonist
BIBO3304TF. BIBO3304TF significantly attenuated the pressor response to NPY (n = 5; P < .02). B, Effect
of NPY on RBF in anesthetized rats, before and after attenuation with Y-1 antagonist BIBO3304TF.
BIBO3304TF significantly attenuated the vasoconstrictive response to NPY (n = 5; P < .05).
Fig 2. Effect of chronic administration of BIBO3304TF
on development of 2K1C RVH. SBP is 26 mm Hg lower
in BIBO3304TF-treated rats (dashed line) than in clipped
controls (P < .01).
A B
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the sympathetic nervous system is also important in
the development and maintenance of hypertension.
In human beings with RVH, epinephrine and nor-
epinephrine levels are higher in renal venous blood of
the ischemic kidney than in either arterial blood or the
renal venous blood of the normal kidney.11 These ele-
vations correlate with elevated plasma renin activity in
renal venous blood. Norepinephrine plasma concen-
tration and renal neurogenic tone are elevated in early
hypertensive 2K, 1C animals in comparison with
unclipped animals.2,12 Norepinephrine is known to
cause renal artery constriction, raise renal perfusion
pressure, decrease RBF, and increase sodium reabsorp-
tion. It has been shown to stimulate renin release,
probably through direct effects on the juxtaglomeru-
lar cells.2 Despite these findings, an increase in sympa-
thetic activity as a mediator of chronic RVH has not
been well established. Norepinephrine levels do not
change after correction of renal artery stenosis in
RVH.13 Hypertension induced from chronic renal fail-
ure in humans has been shown to correlate with
increased sympathetic tone but not with an increase in
plasma epinephrine levels or renin activity.14 Finally,
the affinity of the α 1 and α 2 receptors—the target
sites of norepinephrine-induced vasoconstriction—
does not appear to be increased in 2K, 1C RVH.15
Thus, without changes in circulating levels of norepi-
nephrine or an increase in the receptor affinity for nor-
epinephrine, one remaining possibility is that smooth
muscle cells have become more sensitive to endoge-
nous vasoconstrictors.
NPY is a 36-amino acid polypeptide co-stored
with norepinephrine in postganglionic sympathetic
nerve endings. Five receptor subtypes have been
identified, of which Y-1 is the best characterized.
This postsynaptic receptor mediates a potent vaso-
constrictor response that is not blocked by α- or β-
adrenergic antagonists.16 Furthermore, NPY at low
doses potentiates the effect of norepinephrine to fur-
ther increase blood pressure. Mice lacking the Y1
receptor have a basal blood pressure and heart rate
similar to those in wild-type controls but lack the
ability to potentiate norepinephrine-induced vaso-
constriction.17 NPY has been described as a sympa-
thetic stress hormone that through direct and indi-
rect effects amplifies vasoconstriction, particularly in
small resistance arterioles.7
NPY, like norepinephrine, can be localized to the
renal vasculature and the renal cortex and corti-
comedullary interface. In the primate model, NPY
administered intravenously into the renal artery
resulted in dose-dependent increases in renal artery
resistance and decreases in RBF.18 These effects on
renal hemodynamics are in agreement with our ini-
tial studies on normal anesthetized rats, which
demonstrated decreases in RBF of 25.8% ± 3.6%
after NPY administration. In addition to its vaso-
constrictor effects, NPY also appears to indepen-
dently enhance diuresis and natriuresis through
direct tubular effects.19
Few studies have examined the role of NPY in
RVH. A human study failed to show a difference in
renal vein NPY concentrations between stenotic and
nonstenotic kidneys or between patients with activa-
tion of the renin-angiotensin system and patients
without activation.20 In the pig kidney, direct sym-
pathetic renal nerve stimulation has been demon-
strated to cause an overflow of norepinephrine and
NPY from the kidney, accompanied by renal vaso-
constriction.21 Increased sensitivity to NPY, namely,
Fig 3. Effect of NPY on iso-stimulated renin release from
renal cortical slices. Iso significantly increased renin release
(P < .01); however, no significant effect of NPY on stim-
ulated renin release was demonstrated (P = .09).
Effect of NPY on in vitro renin release from renal
cortical slices
Renin release (ngAngI/h/mg/30 min)
NPY- P
n Basal stimulated value
NPY 10–8 mol/L 6 90 ± 53 112 ± 31 NS
NPY 10–7 mol/L 8 191 ± 60 204 ± 88 NS
NPY 10–6 mol/L 8 145 ± 78 95 ± 23 NS 
NS, Not significant.
an augmented pressor response, has also been
demonstrated in 6- to 8-week-old Goldblatt rats.22
Our study demonstrated that continuous Y-1 block-
ade resulted in inhibition of hypertension develop-
ment over the 4-week observation period. The effect
of the antagonist probably did not represent a “non-
specific” reduction in blood pressure, inasmuch as
BIBO3304TF did not result in sustained hemody-
namic changes in the initial acute studies. Thus,
NPY does appear to contribute significantly to the
development of hypertension in this experimental
model. In contrast, Waeber et al23 found that infu-
sion of exogenous NPY prevented development of
hypertension and suppressed renin release in 2K1C
rats at 8 days. These results suggest an ameliorative
rather than a potentiating effect of NPY on early 2K,
1C RVH. It is possible that NPY augments diuresis
and natriuresis during very early 2K, 1C RVH; thus,
the initial overall effect is prevention of hypertension
development. Greater effects on systemic arterial
pressure and renal vascular resistance may occur after
1 to 2 weeks, such that the effective end result of
NPY is now an exacerbation in hypertension. In
addition, rather than exogenous NPY, our study
examined the physiologic role of NPY in RVH with
the use of a novel selective Y-1 inhibitor.
One potentially significant limitation of our
investigation involved the control group in the 4-
week hypertension studies. Ideally, every animal
should have received a pump, the controls being
infused with vehicle only, to account for any effect of
the indwelling pump on blood pressure. However,
sham pumps used in previously published experi-
ments in 2K, 1C rats and other hypertension mod-
els did not demonstrate any effect on the develop-
ment of hypertension.23,24 Thus, we believe that our
conclusions regarding the contribution of NPY to
RVH are valid.
RVH does appear to be associated with sympa-
thetic activation. Concomitant release of NPY
and/or sensitization of the kidney to NPY may
exaggerate sympathetic effects and contribute to the
development of hypertension through the Y-1
receptor. This could occur through the documented
hemodynamic effects of NPY, worsening perfusion
to the juxtaglomerular cells and further stimulating
renin release. The finding of less discrepancy in kid-
ney weights (between the clipped and unclipped kid-
neys) in rats receiving Y-1 inhibition suggests that
NPY may have vasomotor effects that worsen renal
hemodynamics, improved by Y-1 inhibition.
One mechanism for NPY effects on RVH could
involve a direct effect on renin at the parenchymal
level. However, in our studies, NPY (up to 10–6
mol/L) did not affect basal renin release in kidney
cortical slices. The addition of NPY to iso-stimulat-
ed kidney cortical slices did tend to suppress adren-
ergic-stimulated renin release, but this trend is the
opposite of what we would expect if NPY con-
tributed to adrenergic-mediated renin secretion.
Thus, our results from cortical kidney slices fail to
show a positive effect of NPY on renin release.
Other studies have similarly found that NPY inhibits
adrenergically stimulated renin release, although we
were able to demonstrate only a trend towards this
effect.25-27 The effect of Y-1 inhibition on plasma
renin activity in vivo should be further investigated.
In conclusion, selective Y-1 blockade blunted the
development of hypertension in 2K, 1C RVH, indi-
cating a potential role for NPY in the hypertensive
response to unilateral renal artery stenosis. In vitro
studies failed to support a direct augmentative effect
on basal or iso-stimulated renin release as a mecha-
nism. The mechanism for this NPY effect on blood
pressure could be a direct vasoconstrictor action or
augmentation of enhanced sympathetic activity.
Further studies may elaborate the significance and
mechanism of NPY’s effect on systemic and renal
hemodynamic responses in RVH.
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